Dr. Lal Path Labs Ltd. — Investor Meet, 06-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Dr. Lal PathLabs delivered Q2 FY26 revenue of Rs. 731 Cr (+10.7%) and H1 revenue of Rs. 1,400 Cr (+11%). Q2 EBITDA hit Rs. 224 Cr (30.7% margin) and PAT rose 16.4% to Rs. 152 Cr. An interim dividend of Rs. 7/share and a 1:1 bonus issue were announced. Management maintains FY26 revenue guidance of 11-12% and projects 27-28% EBITDA margins due to efficiency and mix. Strategic priorities include advanced diagnostics, Swasthfit, and expanding into Tier-3/4 towns. No price hikes are planned this year, with GST benefits passed to customers. Radiology pilots and South India acquisitions are in focus, aiming for long-term 13-14% CAGR. The company's tone is confident.